Structure via PubChem · Public domain (PubChem)
bromocriptine
Also known as PLO154, 2-bromoergocryptine, bromocryptine, CB-154, Parlodel®, (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman, 2-bromo-alpha-ergokryptine, 2-bromo-alpha-ergokryptin
Bromocriptine, sold under the brand name Parlodel among others, is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and, as an adjunct, type 2 diabetes.
Key facts
- Drug.StdInChI
- 1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
- Drug.StdInChIKey
- OZVBMTJYIDMWIL-AYFBDAFISA-N
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 459983915
- Drug.image
- Bromocriptine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200px
- Drug.image2
- Bromocriptine molecule ball.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 250px
- Drug.tradename
- Parlodel, others
- Drug.MedlinePlus
~8 min read
Article
11 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacodynamics
- Chemistry
- History
- Society and culture
- Brand names
- See also
- References
- External links
Bromocriptine, sold under the brand name Parlodel among others, is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and, as an adjunct, type 2 diabetes.
It was patented in 1968 and approved for medical use in 1975.